Terapia S.A.

This site focuses strongly on bioequivalence and bioavailability research, with studies designed to compare established medicines and support the development of reliable treatment options across multiple therapeutic areas.

• Research in neurology and psychiatry, including ADHD, epilepsy, bipolar disorder, and major depressive disorder, aims to evaluate how well treatments perform and are tolerated.
• Oncology trials examine cancers such as chronic myeloid leukemia, prostate cancer, melanoma, and other solid tumors, supporting the assessment of new or comparable therapies.
• Immune system and inflammatory diseases, including rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis, are studied to improve treatment effectiveness and patient outcomes.

The portfolio also includes work in infectious diseases, metabolic disorders, and genetic conditions, reflecting a broad research program at the Cluj Napoca site.

Clinical trials in these areas explore therapies for digestive system diseases, immune-mediated conditions, and viral and bacterial infections, with the goal of improving treatment performance and expanding options for patients.

• Crohn’s disease and ulcerative colitis are key digestive conditions studied to better understand treatment response in chronic intestinal inflammation.
• Atopic dermatitis, psoriatic arthritis, rheumatoid arthritis, and axial spondyloarthritis highlight research into immune-driven inflammatory disorders.
• Cluj Napoca also contributes to studies in infectious diseases, including cytomegalovirus infection and other hard-to-treat viral conditions.

These trials help compare treatment options and support better care for both chronic inflammatory illness and infection-related disease.

A substantial portion of the research at Terapia S.A. addresses nervous system diseases and mental disorders, with studies centered on improving symptom control, safety, and overall treatment value.

• ADHD research includes work on attention and behavioral symptoms in both pediatric and adult populations.
• Epilepsy and epileptic seizures are studied to evaluate therapies that may help reduce seizure burden and improve daily functioning.
• Depression, seasonal affective disorder, alcohol dependence, and binge eating disorder reflect broader interest in mental health and behavioral medicine.

The emphasis is on testing treatment options that may offer more consistent outcomes for people living with long-term neurological and psychiatric conditions.

The site conducts studies in neoplasms and blood cancers, focusing on whether established and emerging therapies can provide effective disease control in oncology settings.

• Chronic myeloid leukemia, acute lymphoblastic leukemia, and myelofibrosis are part of the hematology research portfolio.
• Melanoma, non-small cell lung cancer, thyroid cancer, and prostate cancer represent major solid tumor areas under study.
• Some trials also address mutated solid tumors and other advanced cancers to help clarify treatment usefulness across different cancer types.

These investigations support the broader goal of comparing therapies and strengthening evidence for cancer care.

Research in nutritional and metabolic diseases, male urogenital diseases, and genetic phenomena reflects a diverse program that includes both chronic disease management and pharmacologic evaluation.

• Diabetes is included among the metabolic conditions studied to assess treatment effectiveness in everyday disease control.
• Benign prostatic hyperplasia and prostate cancer represent the urologic and male health focus of the portfolio.
• Cystic fibrosis and other genetically linked conditions show interest in therapies for inherited disease mechanisms.

This work helps determine how well medicines perform across distinct patient groups and clinical needs.